TORONTO, Dec. 12 /PRNewswire-FirstCall/ - Bradmer Pharmaceuticals Inc., a biopharmaceutical company dedicated to the development and commercialization of cancer therapies, today announced that Keith L. Black, M.D. and Roger Stupp, M.D. have agreed to join the Company’s Scientific Advisory Board. Dr. Black is one of the leading neuro-oncology surgeons in North America, having performed more than 5,000 operations for the resection of brain tumors, the preliminary step in the standard of care of primary glioblastoma multiforme, Bradmer’s lead indication. Dr. Stupp’s leadership role in European and international cancer research is exemplified by his appointment as the Chairman of the Clinical Research Division of the European Organisation for Research and Treatment of Cancer (EORTC), and his role as lead investigator for numerous international trials in glioblastoma multiforme.
“Dr. Black and Dr. Stupp’s renowned clinical and research skills in the study of brain cancer will provide a tremendous contribution to our Scientific Advisory Board. Their active patient practice and frontline experience in the treatment of glioblastoma multiforme will benefit our entire team at Bradmer,” said Alan M. Ezrin, Ph.D., President and Chief Executive Officer of Bradmer.
“With the addition of Drs. Black and Stupp and the continued involvement of Drs. Bigner and Zalutsky, we have secured the involvement of the preeminent thought leaders in the study of glioblastoma multiforme from the leading brain cancer centers in North America and Europe,” added Donald W. Kufe, M.D., Chairman of Bradmer’s Scientific Advisory Board.
Dr. Black is currently the Chairman of the Department of Neurosurgery as well as the Director of the Comprehensive Brain Tumor Program at Cedars-Sinai Medical Center in Los Angeles, California. He also serves as the Director of the Maxine Dunitz Neurosurgical Institute and holds the Ruth and Lawrence Harvey Chair in Neuroscience. Among his prior appointments, Dr. Black was the Head of Neuro-Oncology at the UCLA Medical Center in Los Angeles. Dr. Black is currently a member of numerous professional organizations including the American Academy of Neurological Surgery, the Neurosurgical Society of America, the American Association of Neurological Surgeons and the Society for Neuro-oncology. Dr. Black has received countless awards from various academic, community-based and media organizations which include receiving America’s Top Doctors for Cancer award, Special Recognition from the National Academy of Science and appearing on the cover of Time magazine as part of its Heroes of Medicine edition.
Dr. Stupp serves as a Staff Physician at the Multidisciplinary Oncology Center (CePO) at the University Hospital in Lausanne, Switzerland (CHUV), with special interests in the treatment of malignant brain tumors, head and neck and lung cancer, and in particular the development of new drugs and the association of chemotherapy and radiation. He is co-president of the neurooncology section of the Swiss Cooperative Group for Clinical Cancer Research, and serves as secretary of the Brain Tumor Group of the European Association for Research and Treatment of Cancer (EORTC) and chair of the EORTC Clinical Research Division. Dr. Stupp has chaired and published results from recent large international randomized trials evaluating new treatments for glioblastoma multiforme.
About Bradmer Pharmaceuticals Inc. (www.bradmerpharma.com)
Bradmer Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of new and innovative cancer therapies. Bradmer’s lead clinical candidate, Neuradiab, was developed at Duke University Medical Center as a proprietary therapy for a particularly aggressive form of brain cancer, glioblastoma multiforme. To date, over US$60 million in grants and related support has driven research and development of the licensed treatment, which has been delivered to over 200 patients with promising results and has completed Phase II clinical trials at Duke University. Bradmer is currently in the process of organizing a pivotal multi-center clinical trial of the licensed treatment. Neuradiab has been granted Orphan Drug Status by both the U.S. Food and Drug Administration and the European Medicines Agency.
Bradmer Pharmaceuticals Inc.'s common shares have not been registered under the Securities Act of 1933, as amended (the “Securities Act”) or any state regulatory agency in the United States. The resale or transfer by a U.S. investor of such common shares of Bradmer Pharmaceuticals Inc. is subject to the requirements of Rule 904 of Regulation S of the Securities Act or such other applicable exemption thereunder, and other applicable state securities laws.
Except for historical information, this press release may contain forward-looking statements, which reflect the Company’s current expectation regarding future events. These forward-looking statements involve risks and uncertainties, which may include but are not limited to, the receipt of all regulatory approvals required to conduct the proposed clinical trial of Neuradiab, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company’s ongoing quarterly and annual reporting.
CONTACT: Bradmer Pharmaceuticals Inc., Mr. Brian Brohman, Chief Business
Officer, Phone: (416) 361-6058 (Ext. 804), E-mail:
bbrohman@bradmerpharma.com, Internet: www.bradmerpharma.com; Investor
Relations, Ross Marshall, The Equicom Group Inc., Phone: (416) 815-0700
(Ext. 238), Fax: (416) 815-0080, E-mail: rmarshall@equicomgroup.com
